{"id":"945a4fb0-be28-5376-b9fe-af09e96e25b4","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:cancer-rad51-rescue","predicate":"increases_in_recorded_comparison","statement":"ALCAR restored impaired RAD51-foci responses under IDH1-inhibited DNA-repair conditions.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"4dddf319-31a6-53a9-88ae-2240a9508a3c","mechanism_event_label":"ALCAR restored impaired RAD51-foci responses under IDH1-inhibited DNA-repair conditions.","subject":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"object":{"id":"3013232a-e89c-55f6-afbf-e9f3d45eb0d6","slug":"human-cancer-rad51-foci","display_name":"Human cancer-cell RAD51 repair foci","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"4dddf319-31a6-53a9-88ae-2240a9508a3c","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:cancer-rad51-rescue-event","event_type":"experimental_observation","label":"ALCAR restored impaired RAD51-foci responses under IDH1-inhibited DNA-repair conditions.","description":"### cancer-rad51-rescue\n\nALCAR restored impaired RAD51-foci responses under IDH1-inhibited DNA-repair conditions.\nRAD51 recruitment is a repair readout, not proof that ALCAR prevents cancer or that a dietary dose changes tumor survival.\nModel and exposure: Human U2OS inducible double-strand-break system; Fig. 4h. Methods: ALCAR 1 mM, GSK864 10 micromolar for five days before induced breaks.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: αKG-mediated carnitine synthesis drives DNA repair via histone acetylation. | 2026 | https://pubmed.ncbi.nlm.nih.gov/42203879/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC13307467/ | https://doi.org/10.1038/s41586-026-10584-7 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"ALCAR plus IDH1 inhibition","sequence_order":0,"notes":""},{"entity":{"id":"3013232a-e89c-55f6-afbf-e9f3d45eb0d6","slug":"human-cancer-rad51-foci","display_name":"Human cancer-cell RAD51 repair foci","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""},{"entity":{"id":"628ddc2d-e4d9-59c7-ae76-0c0cab80a6b1","slug":"2-oxoglutarate","display_name":"2-Oxoglutarate","entity_type_key":"small_molecule"},"role":"upstream metabolic context","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"ALCAR plus IDH1 inhibition\", \"comparator\": \"IDH1 inhibition without ALCAR\", \"endpoint\": \"ALCAR restored impaired RAD51-foci responses under IDH1-inhibited DNA-repair conditions.\", \"effect_direction\": \"increase\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Human U2OS inducible double-strand-break system; Fig. 4h. Methods: ALCAR 1 mM, GSK864 10 micromolar for five days before induced breaks.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived curation with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"ALCAR restored impaired RAD51-foci responses under IDH1-inhibited DNA-repair conditions.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"αKG-mediated carnitine synthesis drives DNA repair via histone acetylation. | https://pubmed.ncbi.nlm.nih.gov/42203879/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC13307467/ | https://doi.org/10.1038/s41586-026-10584-7","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference cancer-rad51-rescue; RAD51 recruitment is a repair readout, not proof that ALCAR prevents cancer or that a dietary dose changes tumor survival.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"e0ac6d77-e8bd-547c-90a5-cd075dace2ad","evidence_kind":"source_excerpt","locator":"Lines 344-350","start_line":344,"end_line":350,"excerpt":"### cancer-rad51-rescue\n\nALCAR restored impaired RAD51-foci responses under IDH1-inhibited DNA-repair conditions.\nRAD51 recruitment is a repair readout, not proof that ALCAR prevents cancer or that a dietary dose changes tumor survival.\nModel and exposure: Human U2OS inducible double-strand-break system; Fig. 4h. Methods: ALCAR 1 mM, GSK864 10 micromolar for five days before induced breaks.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: αKG-mediated carnitine synthesis drives DNA repair via histone acetylation. | 2026 | https://pubmed.ncbi.nlm.nih.gov/42203879/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC13307467/ | https://doi.org/10.1038/s41586-026-10584-7 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Human U2OS inducible double-strand-break system; Fig. 4h. Methods: ALCAR 1 mM, GSK864 10 micromolar for five days before induced breaks.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2588f904-245a-597a-8a12-65118013fb90","stable_key":"import-e3f6ce02-0bd7-5103-acc1-68503ab6751b","title":"Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed.","file_path":"","sha256":"84cc82d6fbb0fd5d73c4ce779e9f88e7f0184ba2d29b18ad0f153815380f2975","revision_id":"dac7a950-dbe5-5c7a-9c70-2ea711d5c71a","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}